Protein Kinase Inhibitors

"Protein Kinase Inhibitors" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

Agents that inhibit PROTEIN KINASES.

Descriptor ID	D047428
MeSH Number(s)	D27.505.519.389.755
Concept/Terms	Protein Kinase Inhibitors Protein Kinase Inhibitors Inhibitors, Protein Kinase Kinase Inhibitors, Protein

Below are MeSH descriptors whose meaning is more general than "Protein Kinase Inhibitors".

Chemicals and Drugs [D]
Chemical Actions and Uses [D27]
Pharmacologic Actions [D27.505]
Molecular Mechanisms of Pharmacological Action [D27.505.519]
Enzyme Inhibitors [D27.505.519.389]
Protein Kinase Inhibitors [D27.505.519.389.755]

Below are MeSH descriptors whose meaning is related to "Protein Kinase Inhibitors".

Below are MeSH descriptors whose meaning is more specific than "Protein Kinase Inhibitors".

Protein Kinase Inhibitors
Janus Kinase Inhibitors

publications

Timeline | Most Recent

This graph shows the total number of publications written about "Protein Kinase Inhibitors" by people in this website by year, and whether "Protein Kinase Inhibitors" was a major or minor topic of these publications.

Bar chart showing 1881 publications over 30 distinct years, with a maximum of 160 publications in 2017

To see the data from this visualization as text, click here.

Year	Major Topic	Minor Topic	Total
1991	0	1	1
1992	1	0	1
1993	1	3	4
1994	0	4	4
1995	1	1	2
1997	0	1	1
1998	0	1	1
1999	1	0	1
2000	2	0	2
2001	0	2	2
2002	0	3	3
2003	0	4	4
2004	5	9	14
2005	12	13	25
2006	45	24	69
2007	45	34	79
2008	42	34	76
2009	64	32	96
2010	72	41	113
2011	87	42	129
2012	82	60	142
2013	98	48	146
2014	84	52	136
2015	102	50	152
2016	87	48	135
2017	106	54	160
2018	85	43	128
2019	86	54	140
2020	47	43	90
2021	16	9	25

Below are the most recent publications written about "Protein Kinase Inhibitors" by people in Profiles.

Gaspar N, Venkatramani R, Hecker-Nolting S, Melcon SG, Locatelli F, Bautista F, Longhi A, Lervat C, Entz-Werle N, Casanova M, Aerts I, Strauss SJ, Thebaud E, Morland B, Nieto AC, Marec-Berard P, Gambart M, Rossig C, Okpara CE, He C, Dutta L, Campbell-Hewson Q. Lenvatinib with etoposide plus ifosfamide in patients with refractory or relapsed osteosarcoma (ITCC-050): a multicentre, open-label, multicohort, phase 1/2 study. Lancet Oncol. 2021 09; 22(9):1312-1321.

View in: PubMed
Delanghe T, Huyghe J, Lee S, Priem D, Van Coillie S, Gilbert B, Choi SM, Vandenabeele P, Degterev A, Cuny GD, Dondelinger Y, Bertrand MJM. Antioxidant and food additive BHA prevents TNF cytotoxicity by acting as a direct RIPK1 inhibitor. Cell Death Dis. 2021 07 14; 12(7):699.

View in: PubMed
Saxena K, Jabbour E, Issa G, Sasaki K, Ravandi F, Maiti A, Daver N, Kadia T, DiNardo CD, Konopleva M, Cortes JE, Yilmaz M, Chien K, Pierce S, Kantarjian H, Short NJ. Impact of frontline treatment approach on outcomes of myeloid blast phase CML. J Hematol Oncol. 2021 06 15; 14(1):94.

View in: PubMed
Lee CH, Shah AY, Rasco D, Rao A, Taylor MH, Di Simone C, Hsieh JJ, Pinto A, Shaffer DR, Girones Sarrio R, Cohn AL, Vogelzang NJ, Bilen MA, Gunnestad Ribe S, Goksel M, Tennøe ØK, Richards D, Sweis RF, Courtright J, Heinrich D, Jain S, Wu J, Schmidt EV, Perini RF, Kubiak P, Okpara CE, Smith AD, Motzer RJ. Lenvatinib plus pembrolizumab in patients with either treatment-naive or previously treated metastatic renal cell carcinoma (Study 111/KEYNOTE-146): a phase 1b/2 study. Lancet Oncol. 2021 07; 22(7):946-958.

View in: PubMed
Gainor JF, Curigliano G, Kim DW, Lee DH, Besse B, Baik CS, Doebele RC, Cassier PA, Lopes G, Tan DSW, Garralda E, Paz-Ares LG, Cho BC, Gadgeel SM, Thomas M, Liu SV, Taylor MH, Mansfield AS, Zhu VW, Clifford C, Zhang H, Palmer M, Green J, Turner CD, Subbiah V. Pralsetinib for RET fusion-positive non-small-cell lung cancer (ARROW): a multi-cohort, open-label, phase 1/2 study. Lancet Oncol. 2021 07; 22(7):959-969.

View in: PubMed
Kadia TM. FLT3 inhibitors in acute myeloid leukemia: increasing options. Clin Adv Hematol Oncol. 2021 Jun; 19(6):352-355.

View in: PubMed
Galle PR, Finn RS, Qin S, Ikeda M, Zhu AX, Kim TY, Kudo M, Breder V, Merle P, Kaseb A, Li D, Mulla S, Verret W, Xu DZ, Hernandez S, Ding B, Liu J, Huang C, Lim HY, Cheng AL, Ducreux M. Patient-reported outcomes with atezolizumab plus bevacizumab versus sorafenib in patients with unresectable hepatocellular carcinoma (IMbrave150): an open-label, randomised, phase 3 trial. Lancet Oncol. 2021 07; 22(7):991-1001.

View in: PubMed
Peng DH, Rodriguez BL, Diao L, Gaudreau PO, Padhye A, Konen JM, Ochieng JK, Class CA, Fradette JJ, Gibson L, Chen L, Wang J, Byers LA, Gibbons DL. Th17 cells contribute to combination MEK inhibitor and anti-PD-L1 therapy resistance in KRAS/p53 mutant lung cancers. Nat Commun. 2021 05 10; 12(1):2606.

View in: PubMed
Nebhan CA, Johnson DB, Sullivan RJ, Amaria RN, Flaherty KT, Sosman JA, Davies MA. Efficacy and Safety of Trametinib in Non-V600 BRAF Mutant Melanoma: A Phase II Study. Oncologist. 2021 09; 26(9):731-e1498.

View in: PubMed
Wiele AJ, Bathala TK, Hahn AW, Xiao L, Duran M, Ross JA, Jonasch E, Shah AY, Campbell MT, Msaouel P, Tannir NM. Lenvatinib with or Without Everolimus in Patients with Metastatic Renal Cell Carcinoma After Immune Checkpoint Inhibitors and Vascular Endothelial Growth Factor Receptor-Tyrosine Kinase Inhibitor Therapies. Oncologist. 2021 06; 26(6):476-482.

View in: PubMed

People

Explore

Similar Concepts

Top Journals